Updated: Oct 15
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case follows a Russian patient with relapsed multiple myeloma who traveled to China after chemotherapy, autologous stem cell transplantation, and consolidation treatment were followed by renewed disease progression. Within 29 days of receiving BCMA CAR-T Treated Relapsed Multiple Myeloma, testing showed no detectable malignant cells in his bone marrow and imaging confirmed complete remission. For international patients with relapsed or refractory multiple myeloma, ChinaCureLink can help coordinate specialist case review and access to advanced cellular therapy in China.
Key Takeaways |
|
Patient Background
The patient, using the alias Alexei, was diagnosed with multiple myeloma in March 2023.
Over the following two years, he underwent multiple lines of treatment, including chemotherapy, an autologous stem cell transplant, and subsequent consolidation therapy. These treatments initially formed a comprehensive treatment strategy, but the disease eventually progressed.
In June 2025, malignant plasma cells were again detected in his bone marrow. His serum free lambda light chain level had risen sharply to 1,930 mg/L, indicating significant disease activity and the need for another treatment strategy.
With conventional treatment no longer controlling the disease, Alexei began looking beyond Russia for another option. Despite the distance and language barrier, he traveled to China for specialist evaluation and treatment.
The Care Team and Approach
Alexei was admitted to a top hematology hospital in China, where his care was coordinated by an experienced hematology and cellular-therapy team led by Dr. Elena Morozova (pseudonym).
The team first carried out a comprehensive assessment to establish the extent of his disease and determine whether CAR-T therapy was appropriate.
Testing showed:
Bone marrow morphology: abnormal plasma cells accounted for 9% of nucleated cells.
Flow cytometry: 1.07% of cells were malignant monoclonal plasma cells.
Bone marrow biopsy: plasma-cell tumor infiltration accounted for approximately 40% of nucleated cells.
PET/CT: multiple metabolically active bone lesions throughout the body, particularly involving the upper left femur, left seventh rib, right pubic bone, and ischium, with some lesions associated with pathological fractures.
Immunofixation electrophoresis: lambda-chain positive.
Serum free lambda light chains: 727 mg/L.
Urine free lambda light chains: 3,490 mg/L.
Based on the findings, the team selected autologous BCMA-targeted CAR-T cell therapy.
BCMA, or B-cell maturation antigen, is a protein commonly found on malignant plasma cells in multiple myeloma. CAR-T therapy works by collecting a patient's own T cells, modifying them outside the body so they can recognize a target such as BCMA, expanding the modified cells, and then returning them to the patient to attack cancerous cells.
On July 28, the team successfully collected Alexei's T cells for manufacturing. After the necessary preparatory chemotherapy, the modified CAR-T cells were infused back into his body on August 12.
Relapsed Multiple Myeloma Timeline/ Process
In Russia
March 2023: Diagnosed with multiple myeloma.
2023–2025: Underwent multiple rounds of chemotherapy, autologous stem cell transplantation, and consolidation treatment.
June 2025: Disease progressed, with malignant plasma cells returning to the bone marrow.
Serum free lambda light chains rose to 1,930 mg/L.
Sought another treatment option outside Russia.
In China — Assessment and CAR-T Preparation
July 24, 2025: Arrived at a top hematology hospital in China and was admitted to the hematology department.
Underwent comprehensive bone marrow, biopsy, PET/CT, blood, urine, and immunological testing.
Results confirmed active multiple myeloma involving the bone marrow and multiple skeletal sites.
July 28: T cells were collected for autologous CAR-T manufacturing.
Completed the necessary chemotherapy preparation before infusion.
CAR-T Treatment and Response
August 12, 2025: Received autologous BCMA-targeted CAR-T cell therapy.
Early treatment period: Experienced a mild cytokine release reaction that was quickly controlled.
Day 19: Lambda-chain testing became negative, while key serum and urine disease markers fell substantially toward normal levels.
Day 29: Bone marrow minimal residual disease testing showed no malignant cells.
Day 29: PET/CT showed markedly reduced metabolic activity across previously involved bones, confirming complete remission.
Following discharge: Received a structured follow-up and rehabilitation plan covering repeat testing, biochemical monitoring, and medication guidance.
Outcome
Twenty-nine days after CAR-T infusion, Alexei's bone marrow minimal residual disease assessment showed no malignant cells, while PET/CT demonstrated a substantial reduction in metabolic activity across his skeletal lesions. Together, these findings confirmed complete remission.
His treatment course was also notable for a limited acute toxicity profile: he experienced only a mild cytokine release reaction, which was rapidly controlled.
Before returning home, the care team established a follow-up plan covering repeat examinations, biochemical monitoring, and medication guidance. Alexei planned to return to China two months later for another review.
How ChinaCureLink Can Help International Patients to Access This Treatment
Alexei's case demonstrates how an international patient with relapsed multiple myeloma can travel to China for specialist assessment and advanced cellular therapy after previous treatment has stopped controlling the disease.
ChinaCureLink helps international patients begin with a comprehensive medical case review, including treatment history, pathology, imaging, laboratory results, and previous transplant or cellular-therapy records. We then coordinate specialist evaluation, hospital matching, treatment scheduling, medical record translation, and the practical logistics of traveling to China for treatment.
For patients with relapsed or refractory multiple myeloma who are exploring BCMA-targeted CAR-T therapy, an individual specialist assessment is the starting point for determining whether this approach is appropriate.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Can international multiple myeloma patients receive BCMA CAR-T therapy in China?
International patients can seek specialist evaluation for BCMA-targeted CAR-T therapy in China. Eligibility depends on the patient's diagnosis, previous treatments, current disease status, overall condition, and the receiving medical team's assessment.
What medical records are needed to apply for CAR-T treatment in China?
A case review typically requires pathology and bone marrow reports, PET/CT or other imaging, blood and biochemical results, treatment history, previous transplant records, and details of prior therapies. ChinaCureLink can help organize and translate these records for specialist review.
How long does it take to arrange CAR-T treatment in China for an international patient?
The timeline depends on the patient's medical condition, completeness of the records, specialist assessment, treatment eligibility, and CAR-T manufacturing requirements. ChinaCureLink coordinates the medical review and scheduling process so the patient can move from initial assessment to treatment as efficiently as possible.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This account reflects one patient's individual experience, which will vary by case, diagnosis stage, and other clinical factors. ChinaCureLink facilitates access to hospitals and treatment coordination — we do not provide medical care ourselves, and this content is not medical advice. Patients and families should consult a qualified hematologist-oncologist before making treatment decisions.
